If recent clinical trial results are a barometer, changes may be in store for patients who live with heart failure or survive a heart attack. During the European Society of Cardiology Congress earlier this fall in Barcelona, researchers presented findings that may encourage the use of new drugs or procedures and raise questions about those currently in use.
One of the most significant studies discussed at the conference and published simultaneously in the New England Journal of Medicine demonstrated the clinical potential of an investigational heart failure drug, LCZ696 (McMurray JJ et al. N Engl J Med. 2014;371:993-1004).
Hampton T. Clinical Trial Results May Lead to Changes in Cardiovascular Care. JAMA. 2014;312(19):1957-1958. doi:10.1001/jama.2014.14319